AI assistant
AMICUS THERAPEUTICS, INC. — Director's Dealing 2014
Oct 2, 2014
31523_dirs_2014-10-02_c925e294-d88a-4f36-8ae8-d91274b7c3e5.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AMICUS THERAPEUTICS INC (FOLD)
CIK: 0001178879
Period of Report: 2014-10-02
Reporting Person: Castelli Jeff (VP, Program Management)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2014-10-02 | Common stock | P | 10208 | $6.0054 | Acquired | 60208 | Direct |
| 2014-10-02 | Common stock | S | 10208 | $6.0054 | Disposed | 50000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2014-10-02 | Stock Options (right to buy) | $2.52 | M | 10208 | Disposed | 2023-06-18 | Common Stock (10208) | Direct |
Footnotes
F1: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 2, 2014.
F2: This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $6.00 to $6.05. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
F3: This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $6.00 to $6.05. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.